Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Anifera Ltd.

Anifera aims to be the leader in developing solutions for adjunct therapy with antibiotics; therefore, improving their efficacy and ultimately reducing their use in animals. Anifera’s technology consists of a family of small molecules which, acting through a novel mechanism of action, have been shown to increase the susceptibility of resistant strains of bacteria to antibiotics. With an initial focus on bovine mastitis, significant benefits are expected if the compounds produce a superior bacterial cure. The company was formed by Stonehaven Incubate and Agile Sciences in 2020. *

 

Period Start 2020-01-01 established
Products Industry animal health
  Industry 2 veterinary drug_o
     
  Street 7-12 Tavistock Square
  City WC1H 9LT London
    Address record changed: 2021-09-14
     
Basic data Employees n. a.
     
    * Document for »About Section«: Anifera Ltd.. (9/14/21). "Press Release: Anifera Awarded Seed Funding for Research from UK’s Centre for Innovation Excellence in Livestock (CIEL)". London.
     
   
Record changed: 2021-09-14

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Anifera Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top